Company Overview
Lunai Bioworks Inc. operates as a pre-clinical stage biotechnology company focused on the development of medicine, diagnostics, and biodefense products for markets in the United States and the Netherlands. The organization functions through three distinct segments identified as RENB, BioSymetrics, and RENC, with a primary research focus on developing a genetically modified allogeneic dendritic cell. Situated within the broader Healthcare sector and specifically the Biotechnology industry, the company targets specialized therapeutic areas that often require significant capital investment before reaching commercialization. Lunai Bioworks Inc. currently maintains a market capitalization of $9.98M and employs a workforce of 29 individuals to execute its strategic roadmap. The combination of a sub-$10 million market cap and the absence of reported annual revenue figures indicates that the company remains in an early-stage development phase, where value is derived primarily from intellectual property and pipeline potential rather than established cash flow generation.
Financial Health
The company reports a net income of $-125,523,440 for the trailing twelve months, while revenue and EBITDA figures are not disclosed in the available data. Although specific revenue numbers are unavailable, the substantial net loss suggests a cost structure dominated by research and development expenses typical of pre-clinical biotechnology firms operating before product launch. The free cash flow stands at $-8,343,209, indicating a negative cash conversion where operating activities are consuming cash reserves rather than generating liquidity for operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting that the company has not yet achieved profitability or generated sufficient revenue to calculate standard margins. The balance sheet shows cash holdings of $491,645 against total debt of $2.75M, resulting in a debt-to-equity ratio that is not available due to the equity structure. The current ratio is 0.03, which signifies a severe liquidity constraint where current assets are insufficient to cover current liabilities without external financing. Return on Equity is reported at -366.4% and Return on Assets at -13.3%, revealing that management is utilizing shareholder capital and assets to generate significant negative returns consistent with a company that has not yet transitioned to a revenue-generating model.
Valuation Assessment
Trailing and forward P/E ratios are both listed as N/A because the company is currently unprofitable, implying that traditional earnings-based valuation methods are not applicable until the business achieves consistent earnings. The price-to-book ratio is -0.74, a negative figure that suggests the market values the company below its book value, a common occurrence for biotechnology firms with significant intangible assets that are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA of -0.98 are also not available or negative, further highlighting the speculative nature of the valuation based on potential future milestones rather than current financial performance. The stock has exhibited significant volatility with a 52-week high of $7.34 and a 52-week low of $0.15, indicating a wide trading range driven by biotech sector sentiment and development updates. The current price position relative to this range is difficult to quantify precisely without real-time data, but the span between the high and low demonstrates extreme price sensitivity common in small-cap biotechnology equities. The beta value of 0.56 indicates that the stock's price volatility is less than that of the broader market, suggesting it moves with lower intensity than the overall equity index despite its small market cap.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both reported as N/A, as the company has not yet generated positive revenue streams to calculate growth rates. The absence of historical revenue data prevents a comparison between revenue growth and earnings growth, but the financial profile implies that earnings are currently far behind revenue generation, consistent with the high burn rate observed in the free cash flow metrics. Lunai Bioworks Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all available resources to fund its research and development activities rather than distributing income to shareholders. This non-dividend status is characteristic of pre-clinical biotechnology companies that must prioritize capital expenditure and clinical trial funding over income distribution to shareholders. The overall growth and income profile is defined by a complete reliance on future product development success rather than current earnings or dividend income, creating a high-risk, high-potential-reward financial structure typical of early-stage healthcare ventures.